
Colorectal cancer (CRC) is currently the third most common malignant tumor in the world in terms of incidence rate and the second most common in terms of mortality rate, and the incidence is increasing year by year, and Asia is the region with the highest incidence (51.8%) and mortality rate (52.4%)...

Benign breast lesions, including fibroadenoma, adenosis, papilloma, and benign phyllodes tumors, are prevalent globally and in China. These lesions, while non-cancerous, can mimic malignant tumors [1, 2]. Management of benign breast lesions ranges from observation to excision Emerging minimally invasive...

Triple-negative breast cancer (TNBC), a subtype with high malignancy and poor prognosis, accounts for approximately 15%-20% of all breast cancer subtypes [1]. Due to the lack of estrogen receptor, progesterone receptor, and HER2 expression, TNBC is insensitive to endocrine therapy and HER2-targeted therapy....

EAI141 was a prospective, multi-center trial designed to assess 3′-deoxy-3′-F-fluorothymidine (FLT) PET/CT as a treatment response biomarker. The primary was to evaluate the negative predictive value (NPV) of post-treatment ‘day 14' FLT-uptake (clinically non-responding patients with...

Gastric cancer (GC) constitutes a major global health burden, ranking among the leading causes of cancer-related mortality. Recent epidemiological data reveal staggering annual estimates of 1.23 million new diagnoses and 954,000 deaths worldwide [1, 2], underscoring the urgent need for precision management...